| CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy R Kinstrie, GA Horne, H Morrison, D Irvine, C Munje, EG Castañeda, ... Leukemia 34 (6), 1613-1625, 2020 | 61 | 2020 |
| Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2 C O’Connor, K Yalla, M Salomé, HA Moka, EG Castañeda, PA Eyers, ... Oncotarget 9 (19), 14977, 2018 | 24 | 2018 |
| Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells IM Michelozzi, E Gomez-Castaneda, RVC Pohle, F Cardoso Rodriguez, ... Blood Advances 7 (9), 1725-1738, 2023 | 10 | 2023 |
| An investigation of targeted inhibition of transcription factor activity with pyrrole imidazole polyamide (PA) in chronic myeloid leukemia (CML) blast crisis cells K Hayatigolkhatmi, G Padroni, W Su, L Fang, E Gómez-Castañeda, ... Bioorganic & Medicinal Chemistry Letters 29 (18), 2622-2625, 2019 | 6 | 2019 |
| The enhanced functionality of low-affinity CD19 CAR T cells is associated with activation priming and polyfunctional cytokine phenotype IM Michelozzi, E Gomez-Castaneda, RVC Pohle, FC Rodriguez, J Sufi, ... Blood 136, 52-53, 2020 | 5 | 2020 |
| Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells K Hayatigolkhatmi, G Padroni, W Su, L Fang, E Gómez-Castañeda, ... Blood Cells, Molecules, and Diseases 69, 119-122, 2018 | 5 | 2018 |
| Loss of the centrosomal protein ALMS1 alters lipid metabolism and the regulation of extracellular matrix-related processes B Bea-Mascato, E Gómez-Castañeda, YE Sánchez-Corrales, ... Biology Direct 18 (1), 84, 2023 | 1 | 2023 |
| Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy E Gómez-Castañeda, LEM Hopcroft, S Rogers, C Munje, ... Cancers 14 (21), 5253, 2022 | | 2022 |
| Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy. Cancers 2022, 14, 5253 E Gómez-Castañeda, LEM Hopcroft, S Rogers, C Munje, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy R Kinstrie, GA Horne, H Morrison, D Irvine, C Munje, EG Castañeda, ... Leukemia 34 (7), 1975, 2020 | | 2020 |
| Uncovering the BCR-ABL1 tyrosine kinase independent signature in chronic myeloid leukaemia stem cells E Gómez-Castañeda University of Glasgow, 2018 | | 2018 |
| Oncogene Addiction in Chronic Myeloid Leukaemia L Jackson, E Gómez‐Castañeda, HG Jørgensen, LEM Hopcroft, S Rogers, ... eLS, 1-9, 2017 | | 2017 |
| THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA K Yalla, H Morrison, P Toofan, L Hopcroft, G Horne, C Munje, H Moka, ... HAEMATOLOGICA 102, 231-231, 2017 | | 2017 |
| Gene Expression Profiling of CD93-Selected CP-CML Stem Cells Confirms Their Quiescent Character and Biomarker Potential GA Horne, CR Munje, R Kinstrie, E Gómez-Castañeda, H Wheadon, ... Blood 128 (22), 4231, 2016 | | 2016 |
